Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 95
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Lancet Oncol ; 15(9): e404-14, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25079103

RESUMEN

In 2010, the International Society of Geriatric Oncology (SIOG) developed treatment guidelines for men with prostate cancer who are older than 70 years old. In 2013, a new multidisciplinary SIOG working group was formed to update these recommendations. The consensus of the task force is that older men with prostate cancer should be managed according to their individual health status, not according to age. On the basis of a validated rapid health status screening instrument and simple assessment, the task force recommends that patients are classed into three groups for treatment: healthy or fit patients who should have the same treatment options as younger patients; vulnerable patients with reversible impairment who should receive standard treatment after medical intervention; and frail patients with non-reversible impairment who should receive adapted treatment.


Asunto(s)
Guías de Práctica Clínica como Asunto , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/terapia , Factores de Edad , Anciano , Anciano de 80 o más Años , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Supervivencia sin Enfermedad , Evaluación Geriátrica , Servicios de Salud para Ancianos/normas , Humanos , Cooperación Internacional , Masculino , Pronóstico , Prostatectomía/métodos , Prostatectomía/mortalidad , Neoplasias de la Próstata/patología , Radioterapia Conformacional/métodos , Radioterapia Conformacional/mortalidad , Medición de Riesgo , Sociedades Médicas , Análisis de Supervivencia , Resultado del Tratamiento , Espera Vigilante
2.
Anticancer Drugs ; 25(9): 1081-8, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24849708

RESUMEN

This open-label, phase II trial assessed the efficacy and safety of two doses of nintedanib, a triple angiokinase inhibitor targeting vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor signaling, in patients with metastatic castration-resistant prostate cancer (mCRPC) following progression on docetaxel-based regimens. Patients were randomized to nintedanib 150 mg (arm A, n=40) or 250 mg (arm B, n=41) twice daily for 6 months unless disease progression or adverse events (AEs) led to discontinuation. The primary endpoint was the prostate-specific antigen (PSA) response rate (confirmed PSA decline of ≥20% from baseline). Eighty-one patients were enrolled. The PSA response rate was 0% (0/32) in arm A versus 11.1% (4/36) in arm B (P=0.12); 5.6% of patients (2/36) in arm B showed a PSA reduction of at least 50%. In arm B, the rate of PSA increase was significantly decelerated on treatment versus before treatment (P=0.002). The median progression-free survival was 73.5 and 76.0 days for arm A and arm B, respectively (P=0.3). AEs included gastrointestinal disorders, asthenia, hypertension, and reversible elevated transaminases. The incidence of drug-related serious AEs (no drug-related deaths) was 20.0% (arm A) and 24.4% (arm B). The primary endpoint was not met. Nintedanib (250 mg) showed only modest activity with manageable AEs in patients with mCRPC post-docetaxel.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Indoles/uso terapéutico , Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico , Adenocarcinoma/secundario , Anciano , Anciano de 80 o más Años , Antineoplásicos/efectos adversos , Antineoplásicos/farmacocinética , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Docetaxel , Humanos , Indoles/efectos adversos , Indoles/farmacocinética , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata Resistentes a la Castración/patología , Taxoides/uso terapéutico , Moduladores de Tubulina/uso terapéutico
3.
Bull Cancer ; 111(6): 597-607, 2024 Jun.
Artículo en Francés | MEDLINE | ID: mdl-38749776

RESUMEN

French Guiana is an equatorial, multicultural, overseas territory in South America. The region is unique: a wealthy country with a universal healthcare system, but significant poverty, which bears little resemblance to its neighbors Brazil and Suriname. Cancer is the second leading cause of death. The incidence of cancer is lower than in France, stages are generally more advanced and the prognosis worse. To date, oncology has been organized through a joint venture between local institutions and healthcare professionals and a cancer center in mainland France, in line with the recommendations of the Institut National du Cancer. The implementation of a medical project and a complete medical studies curriculum in French Guiana is a tremendous opportunity for the development of oncology. The main challenges are consolidating medical care for patients, quality control, genetic oncology, molecular biology, implementation of radiotherapy and nuclear medicine, clinical and translational research, and teaching programs. Working in oncology in French Guiana is exciting because of the scientific interest (particular characteristics of cancers, notably the role of viral or micro-organism-induced carcinogenesis, genetic factors in these populations with African and Asian roots, and the importance of a public health policy) and human interest (patients from different cultures; all of them bring original approaches to health and illness that need to be deciphered in order to offer quality care). This requires the support of healthcare professionals who are enthusiastic about this unique adventure.


Asunto(s)
Neoplasias , Humanos , Curriculum , Francia , Guyana Francesa , Oncología Médica/educación , Neoplasias/diagnóstico , Neoplasias/patología , Neoplasias/terapia , Control de Calidad , Investigación Biomédica Traslacional
4.
Bull Cancer ; 110(1): 129-135, 2023 Jan.
Artículo en Francés | MEDLINE | ID: mdl-36150918

RESUMEN

The French National Cancer Institute, in its ten-year roadmap, has defined an axis 4: "ensuring that progress benefits all". The Association francophone sur les soins oncologiques de support wished to take stock of cancer care for gender and sexual minorities. The authors, who have a sociological and oncological background, have gathered the main data from the French-language literature limited to sociological aspects. They address the definitions of sexual orientation, identity and practice, gender identity, expression and assignment, and the issue of intersex. They report on the concrete problems from patients' narratives. Little research has been done on cancer patients. Studies on children and young adolescents focus on other issues (harassment, discrimination, dropping out of school); those on the older persons show the invisibility of the issue. For adults, the organization of the care process is obscured by a purely psychiatric and technical medical approach. The relationship of trust is not established, and the terms and views used lead to delays and breaks in care. To remedy these shortcomings, the authors suggest that training efforts be made (for patients and caregivers), that community associations be supported, and that sociological and medical research be carried out, considering an approach by cancer pathology as well as by sexual or gender minority groups.


Asunto(s)
Neoplasias , Minorías Sexuales y de Género , Adulto , Adolescente , Niño , Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Identidad de Género , Vías Clínicas , Conducta Sexual , Neoplasias/terapia
5.
Lancet Reg Health Am ; 21: 100492, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37139265

RESUMEN

Background: Adult T-cell leukemia/lymphoma (ATL), one of the most aggressive cancers in the world, occurs in 5% of the 10 million people living with HTLV-1 worldwide. French Guiana, a French overseas territory in South America, is one of the highest endemic areas of HTLV-1 worldwide. Here, we describe the demographic and clinical characteristics and outcome of ATL in this area. Methods: We retrospectively collected data from all patients diagnosed between 2009 and 2019. Patients were distributed according to Shimoyama's classification. Prognostic factors were explored through univariate analysis. Findings: Over the 10-year study period, 41 patients with a median age of 54 years at diagnosis were identified, among whom 56% were women. Sixteen (39%) patients were Maroons, a cultural group descendant of the runaway enslaved Africans from former Dutch Guiana. Among the study population, 23 (56%) had an acute type, 14 (34%) a lymphoma type, and one and one chronic and primary cutaneous tumour, respectively. First-lines of treatment included either chemotherapy or Zidovudine combined with pegylated interferon alpha. The 4-year overall survival was 11.4% for the entire population with 0% and 11% for lymphoma and acute forms, respectively. The median progression-free survival was 93 and 115 days for the acute and lymphoma groups (p = 0.37), respectively. Among the twenty-nine patients who died, 8 (28%) died of toxicity, 7 (24%) died of disease progression and the cause of death remained unknown in 14 (48%) patients. Due to the overall poor prognosis, no significant prognostic factors could be identified. Interpretation: This study provides real-life data from ATL patients in French Guiana, a remote territory in a middle-income region. Patients, mostly Maroons, presented with a younger age and the prognosis was worse than expected compared to Japanese patients. Funding: None.

6.
Med Trop Sante Int ; 3(1)2023 03 31.
Artículo en Francés | MEDLINE | ID: mdl-37389381

RESUMEN

Source of many myths, French Guiana represents an exceptional territory due to the richness of its biodiversity and the variety of its communities. The only European territory in Amazonia, surrounded by the Brazilian giant and the little-known Suriname, Ariane 6 rockets are launched from Kourou while 50% of the population lives below the poverty line. This paradoxical situation is a source of health problems specific to this territory, whether they be infectious diseases with unknown germs, intoxications or chronic pathologies.Some infectious diseases such as Q fever, toxoplasmosis, cryptococcosis or HIV infection are in common with temperate countries, but present specificities leading to sometimes different management and medical reasoning. In addition to these pathologies, many tropical diseases are present in an endemic and / or epidemic mode such as malaria, leishmaniasis, Chagas disease, histoplasmosis or dengue. Besides, Amazonian dermatology is extremely varied, ranging from rare but serious pathologies (Buruli ulcer, leprosy) to others which are frequent and benign such as agouti lice (mites of the family Trombiculidae) or papillonitis. Envenomations by wild fauna are not rare, and deserve an appropriate management of the incriminated taxon. Obstetrical, cardiovascular and metabolic cosmopolitan pathologies sometimes take on a particular dimension in French Guiana that must be taken into account in the management of patients. Finally, different types of intoxication are to be known by practitioners, especially due to heavy metals.European-level resources offer diagnostic and therapeutic possibilities that do not exist in the surrounding countries and regions, thus allowing the management of diseases that are not well known elsewhere.Thanks to these same European-level resources, research in Guyana occupies a key place within the Amazon region, despite a smaller population than in the surrounding countries. Thus, certain pathologies such as histoplasmosis of the immunocompromised patient, Amazonian toxoplasmosis or Q fever are hardly described in neighboring countries, probably due to under-diagnosis linked to more limited resources. French Guiana plays a leading role in the study of these diseases.The objective of this overview is to guide health care providers coming to or practicing in French Guiana in their daily practice, but also practitioners taking care of people returning from French Guiana.


Asunto(s)
Enfermedades Transmisibles , Cuniculidae , Infecciones por VIH , Histoplasmosis , Enfermedades no Transmisibles , Fiebre Q , Toxoplasmosis , Animales , Humanos , Guyana Francesa/epidemiología , Toxoplasmosis/diagnóstico
7.
N Engl J Med ; 359(1): 31-42, 2008 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-18596272

RESUMEN

BACKGROUND: The expression of vascular endothelial growth factor (VEGF) is characteristic of differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor clinical outcome. Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT. METHODS: In an open-label, single-group, phase 2 study, we treated 93 patients who had progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer with 125 mg of motesanib diphosphate, administered orally once daily. The primary end point was an objective response as assessed by an independent radiographic review. Additional end points included the duration of the response, progression-free survival, safety, and changes in serum thyroglobulin concentration. RESULTS: Of the 93 patients, 57 (61%) had papillary thyroid carcinoma. The objective response rate was 14%. Stable disease was achieved in 67% of the patients, and stable disease was maintained for 24 weeks or longer in 35%; 8% had progressive disease as the best response. The Kaplan-Meier estimate of the median duration of the response was 32 weeks (the lower limit of the 95% confidence interval [CI] was 24; the upper limit could not be estimated because of an insufficient number of events); the estimate of median progression-free survival was 40 weeks (95% CI, 32 to 50). Among the 75 patients in whom thyroglobulin analysis was performed, 81% had decreased serum thyroglobulin concentrations during treatment, as compared with baseline levels. The most common treatment-related adverse events were diarrhea (in 59% of the patients), hypertension (56%), fatigue (46%), and weight loss (40%). CONCLUSIONS: Motesanib diphosphate can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive. (ClinicalTrials.gov number, NCT00121628.)


Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Papilar/tratamiento farmacológico , Indoles/uso terapéutico , Niacinamida/análogos & derivados , Receptores de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Neoplasias de la Tiroides/tratamiento farmacológico , Adenocarcinoma Folicular/tratamiento farmacológico , Adenocarcinoma Folicular/secundario , Adenoma Oxifílico/tratamiento farmacológico , Adenoma Oxifílico/secundario , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/efectos adversos , Carcinoma Papilar/secundario , Femenino , Genotipo , Humanos , Indoles/efectos adversos , Masculino , Persona de Mediana Edad , Niacinamida/efectos adversos , Niacinamida/uso terapéutico , Oligonucleótidos , Proteínas Proto-Oncogénicas c-kit , Análisis de Supervivencia , Tiroglobulina/sangre , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/patología
8.
Oncology ; 81(5-6): 319-24, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22179558

RESUMEN

OBJECTIVES: Only a few case reports and small case series of patients with sarcoidosis or sarcoid-like reaction and testicular germ cell tumors (GCT) have been reported in the literature. We performed a retrospective study of patients with testicular GCT managed at the Centre Léon-Bérard, who presented granulomatosis. METHODS: We performed a computerized search to identify all male patients with both a diagnosis of sarcoidosis or granuloma and testicular tumors seen at the Centre Léon-Bérard between 1992 and 2008. RESULTS: A total of 13 patients were identified among the 1,182 patients with testicular tumors. The median age at diagnosis of testicular GCT was 25.5 years. Six patients had stage I disease, 2 patients had stage IIb and 5 patients had stage III. Sarcoid-like granulomatosis was found in 9 patients at the time of initial diagnosis and in 4 patients during follow-up. Sarcoidosis presented mainly as pulmonary disease without severe organ involvement, with a benign evolution. CONCLUSION: We advise caution in the interpretation of clinical and histological findings in these patients. Sarcoid-like granulomatosis, a condition that can be combined with testicular cancer, should always be considered in the differential diagnosis of metastatic testicular tumors.


Asunto(s)
Granuloma del Sistema Respiratorio/patología , Neoplasias de Células Germinales y Embrionarias/patología , Sarcoidosis Pulmonar/patología , Neoplasias Testiculares/diagnóstico , Adulto , Diagnóstico Diferencial , Estudios de Seguimiento , Granuloma del Sistema Respiratorio/diagnóstico , Humanos , Masculino , Estadificación de Neoplasias/métodos , Neoplasias de Células Germinales y Embrionarias/diagnóstico , Estudios Retrospectivos , Sarcoidosis Pulmonar/diagnóstico , Neoplasias Testiculares/patología , Adulto Joven
9.
BMC Cancer ; 11: 469, 2011 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22044775

RESUMEN

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is among the most aggressive human malignancies. It is associated with a high rate of local recurrence and with poor prognosis. METHODS: We retrospectively reviewed 44 consecutive patients treated between 1996 and 2010 at Leon Berard Cancer Centre, Lyon, France. The combined treatment strategy derived from the one developed at the Institut Gustave Roussy included total thyroidectomy and cervical lymph-node dissection, when feasible, combined with 2 cycles of doxorubicin (60 mg/m2) and cisplatin (100 mg/m2) Q3W, hyperfractionated (1.2 Gy twice daily) radiation to the neck and upper mediastinum (46-50 Gy), and then four cycles of doxorubicin-cisplatin. RESULTS: Thirty-five patients received the three-phase combined treatment. Complete response after treatment was achieved in 14/44 patients (31.8%). Eight patients had a partial response (18.2%). Twenty-two (50%) had progressive disease. All patients with metastases at diagnosis died shortly afterwards. Thirteen patients are still alive. The median survival of the entire population was 8 months. CONCLUSION: Despite the ultimately dismal prognosis of ATC, multimodality treatment significantly improves local control and appears to afford long-term survival in some patients. There is active ongoing research, and results obtained with new targeted systemic treatment appear encouraging.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Tiroides/terapia , Tiroidectomía , Adulto , Anciano , Anciano de 80 o más Años , Cisplatino/administración & dosificación , Terapia Combinada/métodos , Fraccionamiento de la Dosis de Radiación , Doxorrubicina/administración & dosificación , Femenino , Francia , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Inducción de Remisión , Estudios Retrospectivos , Análisis de Supervivencia , Carcinoma Anaplásico de Tiroides , Neoplasias de la Tiroides/mortalidad
10.
Anticancer Drugs ; 22(7): 688-99, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21200314

RESUMEN

The treatment of metastatic, progressive thyroid cancer has evolved over recent years. New 'targeted' therapeutic approaches have been developed along with advances in the knowledge of thyroid carcinogenesis and the identification of tumor and endothelial targets. In recent years, results of targeted therapies have shown some benefit in refractory, progressive, differentiated, and medullary thyroid carcinomas but not, until recently, in undifferentiated thyroid carcinoma. We review here the different targeted therapies tested in thyroid cancers.


Asunto(s)
Antineoplásicos/farmacología , Sistemas de Liberación de Medicamentos , Neoplasias de la Tiroides/tratamiento farmacológico , Carcinoma Neuroendocrino , Endotelio/efectos de los fármacos , Endotelio/metabolismo , Humanos , Metástasis de la Neoplasia , Neoplasias de la Tiroides/patología
11.
BJU Int ; 106(6): 779-85, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20089110

RESUMEN

OBJECTIVE: To determine whether conformity to standard recommendations of retroperitoneal lymph node dissection (RPLND) after chemotherapy for testicular and primary retroperitoneal nonseminomatous germ cell tumours (NSGCT) and completeness of surgical excision have an effect on oncological outcome. PATIENTS AND METHODS: This was a retrospective study of patients with testicular and primary retroperitoneal NSGCT, with initial involvement of RPLNs, treated between June 1992 and December 2002 in one institution. We reviewed the clinical, surgical and histological charts of 151 such patients who had a RPLND after first-line platinum-based chemotherapy. The recommendations used to define conformity to RPLND standards were: the indication based on initial and residual lymph node size, shrinkage, extension of dissection and completeness of resection. RESULTS: RPLND conformed to standard recommendations in 70 of the 151 (46%) patients. Conformity was complete for the surgeon who operated on 48 patients and was 26% of the others. Fifteen patients (10%) relapsed in the retroperitoneum, 14 of whom had initial lymph nodes of > or =5 cm. Two patients (3%) relapsed in the group of 70 patients with conformed and complete RPLND, vs 13 (16%) in the 81 with conformed but incomplete resection or with non-conformed and complete or incomplete RPLND. After a median (range) follow-up of 77 (1.3-186.5) months 132 patients were alive with no evidence of disease, 18 died and one was alive with progressive disease. The limitations of this study were the relatively few patients and that it was retrospective. CONCLUSION: There was conformity of RLNPD to the recommendations, and completeness of resection, in half of the patients operated; this might have an effect on oncological outcome. Our data suggest that patients should be treated in tertiary centres.


Asunto(s)
Escisión del Ganglio Linfático/métodos , Ganglios Linfáticos/cirugía , Neoplasias de Células Germinales y Embrionarias/cirugía , Neoplasias Retroperitoneales/cirugía , Neoplasias Testiculares/cirugía , Adolescente , Adulto , Anciano , Antineoplásicos/uso terapéutico , Terapia Combinada/métodos , Supervivencia sin Enfermedad , Humanos , Escisión del Ganglio Linfático/normas , Ganglios Linfáticos/patología , Metástasis Linfática , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Neoplasias de Células Germinales y Embrionarias/secundario , Orquiectomía , Pronóstico , Neoplasias Retroperitoneales/tratamiento farmacológico , Neoplasias Retroperitoneales/patología , Espacio Retroperitoneal , Estudios Retrospectivos , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/patología , Resultado del Tratamiento , Adulto Joven
12.
BJU Int ; 106(4): 462-9, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20346033

RESUMEN

Prostate cancer is the most prevalent cancer in men and predominantly affects older men (aged >or=70 years). The median age at diagnosis is 68 years; overall, two-thirds of prostate cancer-related deaths occur in men aged >or=75 years. With the exponential ageing of the population and the increasing life-expectancy in developed countries, the burden of prostate cancer is expected to increase dramatically in the future. To date, no specific guidelines on the management of prostate cancer in older men have been published. The International Society of Geriatric Oncology (SIOG) conducted a systematic bibliographic search based on screening, diagnostic procedures and treatment options for localized and advanced prostate cancer, to develop a proposal for recommendations that should provide the highest standard of care for older men with prostate cancer. The consensus of the SIOG Prostate Cancer Task Force is that older men with prostate cancer should be managed according to their individual health status, which is mainly driven by the severity of associated comorbid conditions, and not according to chronological age. Existing international recommendations (European Association of Urology, National Comprehensive Cancer Network, and American Urological Association) are the backbone for localized and advanced prostate cancer treatment, but need to be adapted to patient health status. Based on a rapid and simple evaluation, patients can be classified into four different groups: 1, 'Healthy' patients (controlled comorbidity, fully independent in daily living activities, no malnutrition) should receive the same treatment as younger patients; 2, 'Vulnerable' patients (reversible impairment) should receive standard treatment after medical intervention; 3, 'Frail' patients (irreversible impairment) should receive adapted treatment; 4, Patients who are 'too sick' with 'terminal illness' should receive only symptomatic palliative treatment.


Asunto(s)
Guías de Práctica Clínica como Asunto , Neoplasias de la Próstata/terapia , Actividades Cotidianas , Factores de Edad , Anciano , Servicios de Salud para Ancianos , Estado de Salud , Humanos , Esperanza de Vida , Masculino , Nomogramas , Neoplasias de la Próstata/diagnóstico
13.
Rev Prat ; 60(2): 205-11, 2010 Feb 20.
Artículo en Francés | MEDLINE | ID: mdl-20225559

RESUMEN

Prostate cancer is the first cancer by incidence in men. However, the mortality rate is only around 15% of the new cases. There is a great heterogeneity of prognosis based on stage serum PSA and pathological prognostic score. The disease occurs in elderly patients (34% are older than 75 years). Patients' population life expectancy and individual chance of surviving is heterogeneous due to very different health status. Therefore decision must take into account both disease severity and health status. This decision making strategy is also true for screening and early diagnosis. To date there is no definite conclusion from randomized trials which support the indication of mass screening. The current recommendation is an individual early diagnosis procedure based on the measure of serum PSA level and Digital Rectal Examination. This procedure may only be proposed after an evaluation of person's health status and full information on consequences of such a procedure.


Asunto(s)
Detección Precoz del Cáncer , Tamizaje Masivo , Neoplasias de la Próstata/diagnóstico , Humanos , Masculino , Estudios Prospectivos
14.
Lancet Oncol ; 10(1): 80-7, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19111248

RESUMEN

There is currently little data showing that older adults can derive benefit from cancer screening. Advancing age is associated with an increasing prevalence of cancer and other chronic conditions, or comorbidity, and questions remain about the interactions between comorbidity and cancer screening in the elderly population. In this Review, we assess the available evidence on the effects of comorbidity on cancer screening in elderly individuals. In view of the high heterogeneity of existing data, consistent recommendations cannot be made. Decisions on cancer screening in older adults should be based on an appropriate assessment of each individual's health status and life expectancy, the benefits and harms of screening procedures, and patient preferences. We suggest that Comprehensive Geriatric Assessment might be a necessary step to identify candidates for cancer screening in the elderly population. Specific clinical trials should be done to improve the evidence and show the effectiveness and cost-effectiveness of cancer screening in older adults.


Asunto(s)
Comorbilidad , Detección Precoz del Cáncer , Neoplasias/diagnóstico , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Trastornos del Conocimiento/complicaciones , Femenino , Estado de Salud , Humanos , Fallo Renal Crónico/complicaciones , Esperanza de Vida , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Sangre Oculta
15.
Crit Rev Oncol Hematol ; 150: 102947, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32294609

RESUMEN

BACKGROUND: There is no clear consensus on the administration of anti-neoplastic agents to patients on peritoneal dialysis. Dose adjustments to prevent serious adverse events are still not established. Thus, the aim of this study was to systematically review current evidence on the use of systemic oncology therapies in peritoneal dialysis. METHODS: A systematic review was conducted using PubMed, Scopus, and Cochrane. All relevant data was collected, including clinical and pharmacokinetic parameters, with comparison to subjects with normal renal function. RESULTS: Sixteen studies were included. All were case reports. Eighteen types of anti-cancer drugs were reviewed. Multiple adverse events and altered pharmacokinetics were reported. CONCLUSION: Data concerning the use of anti-neoplastic drugs in patients on peritoneal dialysis are still sparse. The elimination of anti-cancer agents seems often altered in such patients, resulting in serious adverse events. Based on the available evidence, we suggest the need for dose adjustment of each drug.


Asunto(s)
Antineoplásicos/uso terapéutico , Fallo Renal Crónico/terapia , Diálisis Peritoneal , Humanos
16.
BMC Urol ; 9: 5, 2009 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-19534791

RESUMEN

BACKGROUND: Micropapillary bladder cancer is a rare and aggressive variant of urothelial carcinoma. A retrospective review of our experience in management of patients with muscle-invasive or metastatic micropapillary bladder cancer was performed to better define the behavior of this disease. METHODS: We reviewed the records of the 11 patients with micropapillary bladder cancer who were evaluated and treated at Léon Bérard Cancer Center between 1994 and 2007, accounting for 1,2% of all urothelial tumors treated in this institution. RESULTS: Mean patients age was 60 years. The majority of patients (72%) were diagnosed after 2004. After a median follow-up of 31.7 months, median overall survival was 19 months. Two patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed and had a disease free survival of 9.6 months. CONCLUSION: Micropapillary bladder cancer is probably an underreported variant of urothelial carcinoma associated with poor prognosis. Adjuvant chemotherapy might have a questionable efficacy and the optimal treatment strategy is yet to be defined.


Asunto(s)
Carcinoma Papilar/mortalidad , Carcinoma Papilar/terapia , Neoplasias de la Vejiga Urinaria/mortalidad , Neoplasias de la Vejiga Urinaria/terapia , Anciano , Instituciones Oncológicas , Femenino , Francia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Análisis de Supervivencia , Tasa de Supervivencia , Resultado del Tratamiento
17.
BMC Urol ; 9: 4, 2009 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-19500382

RESUMEN

BACKGROUND: Bladder small cell carcinoma is an uncommon tumour. Through a retrospective study we will present the evolution of recurrent and metastatic disease and outcome of patients treated at Léon-Bérard Cancer Centre. METHODS: Only 15 patients having recurrent or metastatic bladder small cell carcinoma were treated at Léon-Bérard Cancer Centre between 1996 and 2007. The patients were divided in two groups: a mixed small cell carcinoma group (9 patients) and a pure small cell carcinoma group (6 patients). All the records and informations related to treatment and outcome of the 15 patients were retrospectively analyzed. Various characteristics of small cell carcinoma were investigated. RESULTS: The median age of the 15 patients having recurrent or metastatic bladder small cell carcinoma and treated at Léon-Bérard Cancer Centre was 63 years and the disease was at stage IV for all cases. Nine patients were treated by chemotherapy. Four patients were treated by local radiotherapy (3 with radiotherapy without previous surgery and 1 with surgery followed by radiotherapy) and chemotherapy. One patient was treated by whole brain radiotherapy. And one patient died before treatment. After 52.4 months median follow up, 12 patients died. Median overall survival was 7.6 months. Survival probability at 1 year was 33%. Median overall survival was 9.9 months in the mixed small cell carcinoma group, and was only 4.6 months in the pure small cell carcinoma group. Survival probability at 1 year in the mixed small cell carcinoma group was 44% as compared to 17% in the pure small cell carcinoma group (Log-rank test: p = 0.228). CONCLUSION: Recurrent and metastatic bladder small cell carcinoma is associated with very poor prognosis. The pure bladder small cell carcinoma appears to have poorer outcome than the mixed bladder small cell carcinoma. Chemotherapy using platinum drugs is a mainstay treatment.


Asunto(s)
Carcinoma de Células Pequeñas/secundario , Recurrencia Local de Neoplasia/epidemiología , Neoplasias de la Vejiga Urinaria/patología , Anciano , Carcinoma de Células Pequeñas/mortalidad , Carcinoma de Células Pequeñas/terapia , Terapia Combinada , Femenino , Estudios de Seguimiento , Francia/epidemiología , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/terapia , Estudios Retrospectivos , Tasa de Supervivencia , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/mortalidad , Neoplasias de la Vejiga Urinaria/terapia
18.
Rev Prat ; 59(3): 339-42, 344, 2009 Mar 20.
Artículo en Francés | MEDLINE | ID: mdl-19408875

RESUMEN

The decision making process, based on screening, diagnostic, staging, therapeutic and multidisciplinary decision procedures, is very well defined in oncology. Recently the same approach has been applied to the management of senior adult cancer patients. Screening of geriatric problems and evaluation of health status are linked to the oncologic evaluation. A comprehensive knowledge of the different health problems is discussed through a multidisciplinary approach. This needs a specific organization and collaboration between oncologists and geriatricians. It requires also the elaboration of specific decision trees of cancer adapted to the case of senior adult patients.


Asunto(s)
Neoplasias , Anciano , Toma de Decisiones , Geriatría , Humanos , Oncología Médica , Neoplasias/diagnóstico , Neoplasias/terapia
19.
Rev Prat ; 59(3): 347-58, 2009 Mar 20.
Artículo en Francés | MEDLINE | ID: mdl-19408878

RESUMEN

The clinical management of cancer in senior adult patients is based on the results of clinical trials which were performed in adults, generally younger adult patients. It is therefore difficult to assess the feasibility of such treatments, mainly chemotherapy, in older patients. The evaluation of health status is an important step in the decision making of cancer treatment in senior adults. In non Hodgkin lymphomas, the standard treatment remains chemotherapy with Rituximab. Specific protocols and treatment adaptation have been proposed in very old seniors. Surgery is a very efficient treatment in breast cancer, colorectal cancer and sometimes in non small cell lung cancer. Radiotherapy is important in the curative management of prostate cancer and in the multidisciplinary treatment of breast, colorectal and lung cancers. Chemotherapy is generally feasible in senior adults. However, Cisplatin is often too much toxic. Chemotherapy has a palliative impact in the treatment of metastatic prostate and breast cancers. It would be discussed in some high-risk groups of patients with breast and colorectal cancers. New targeted drugs are active in breast, colorectal cancers and in non Hodgkin lymphomas. Indications of treatment tailored on health status evaluation are discussed in the manuscript.


Asunto(s)
Neoplasias/terapia , Anciano , Neoplasias de la Mama/terapia , Neoplasias del Colon/terapia , Árboles de Decisión , Femenino , Humanos , Neoplasias Pulmonares/terapia , Linfoma/terapia , Masculino , Neoplasias de la Próstata/terapia
20.
Eur J Cancer ; 44(4): 488-93, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18242078

RESUMEN

In dealing with older cancer patients undergoing chemotherapy, some form of geriatric evaluation is needed to distinguish those which can be treated as adults from those - the vulnerable ones - who need a modified approach and also from those who are frail or too sick to receive an active treatment. Only scarce data are available to guide treatment of vulnerable or frail patients, the neglected majority of older cancer patients. In most of these cases they receive an adapted approach which does not derive from the results of clinical trials, but from an enlightened empiricism. In this article we summarise and discuss available data for management of the main tumour types in frail and vulnerable patients, and call for further research in this field.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Anciano , Anciano Frágil , Evaluación Geriátrica , Humanos , Poblaciones Vulnerables
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA